Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Researcher

Bart Jacobs

Publications & Research Data

Awards & Distinctions

8 Results

2025

A novel carbohydrate fatty-acid monosulphate ester, squalane-in-water adjuvant is safe and enhances inactivated influenza vaccine immunogenicity in older adults

Valentino D'OnofrioBart JacobsAzhar AlhatemiSimon De GussemMarjolein VerstraeteSharon PorrezAnthony WillemsFien De BoeverGwenn WaerlopGeert Leroux-Roels et al.

A1 Journal Article in VACCINES

Safety and immunogenicity of an adjuvanted clostridioides difficile vaccine candidate in healthy adults : a randomized placebo-controlled phase 1 study

Isabel Leroux-RoelsAzhar AlhatemiMagalie CaubetFien De BoeverBertrand de WergifosseMohamed El IdrissiGuilherme S FerreiraBart JacobsAxel LambertSandra Morel et al.

A1 Journal Article in JOURNAL OF INFECTIOUS DISEASES

2024

Safety and immunogenicity of a 4-component generalized modules for membrane antigens Shigella vaccine in healthy European adults : randomized, phase 1/2 study

Isabel Leroux-RoelsCathy MaesFrancesca ManciniBart JacobsEleanna SarakinouAzhar AlhatemiJasper JoyeSilvia GrappiGiulia Luna CilioAlimamy Serry-Bangura et al.

A1 Journal Article in JOURNAL OF INFECTIOUS DISEASES

Safety and immunogenicity of a carbohydrate fatty acid monosulphate ester adjuvant combined with a low-dose quadrivalent split-virion inactivated influenza vaccine : a randomised, observer-blind, active-controlled, first-in-human, phase 1 study

Valentino D'OnofrioSharon PorrezBart JacobsAzhar AlhatemiFien De BoeverGwenn WaerlopEls MichelsFrancesca VanniAlessandro ManentiGeert Leroux-Roels et al.

A1 Journal Article in VACCINES

Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults : a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial

Isabel Leroux-RoelsChittappen Kandiyil PrajeethAmare AregayNiranjana NairGuus F RimmelzwaanAlbert D M E OsterhausSimone KardinahlSabrina PelzStephan BauerValentino D'Onofrio et al.

A1 Journal Article in LANCET INFECTIOUS DISEASES

2023

Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant

Gwenn WaerlopYorick JanssensBart JacobsFranziska JarczowskiAndré DiessnerGeert Leroux-RoelsVictor KlimyukIsabel Leroux-RoelsFrank Thieme

A1 Journal Article in FRONTIERS IN IMMUNOLOGY

Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate : a randomised, double-blind, placebo-controlled, phase 2a trial

Isabel Leroux-RoelsPaul WillemsGwenn WaerlopYorick JanssensJessika TourneurFien De BoeverJacques BruhwylerAzhar AlhatemiBart JacobsFlorence Nicolas et al.

A1 Journal Article in LANCET INFECTIOUS DISEASES

2022

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine

Isabel Leroux-RoelsCathy MaesJasper JoyeBart JacobsFranziska JarczowskiAndré DiessnerYorick JanssensGwenn WaerlopKirsi TamminenSuvi Heinimäki et al.

A1 Journal Article in FRONTIERS IN IMMUNOLOGY